Condition
RET Gene Mutation
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (3)
Trial Status
Completed1
Active Not Recruiting1
Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05370469Not ApplicableActive Not Recruiting
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
NCT03784378Phase 1Completed
Continued Access to RXDX-105
NCT04161391Phase 1Terminated
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
NCT06109558Phase 1Recruiting
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
Showing all 4 trials